NIH

Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace

Notice NOT-MH-21-125 from the NIH Guide for Grants and Contracts
Categories: NIH

NIH invests in next iteration of public-private partnership to advance precision medicine research for Alzheimer’s disease

NIH News Releases - March 2, 2021 - 7:00pm
Effort is part of the Accelerating Medicines Partnership to enable development of effective targeted therapies.

Categories: NIH

NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms

NIH News Releases - March 2, 2021 - 5:30pm
Study shows the treatment is safe, but provides no significant benefit in this group.

Categories: NIH

Law enforcement seizures of methamphetamine and marijuana rose during pandemic

NIH News Releases - March 2, 2021 - 5:00pm
Findings suggest that the pandemic may have impacted the availability and demand of some, but not all, illegal drugs.

Categories: NIH

NIH effort seeks to understand MIS-C, range of SARS-CoV-2 effects on children

NIH News Releases - March 2, 2021 - 2:15pm
Program to investigate why some children are at greater risk for SARS-CoV-2 infection than others.

Categories: NIH

Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Supported Individual Fellows

NIH Extramural Research & Funding News - March 2, 2021 - 11:39am

We recognize that the high cost of childcare impacts the ability of graduate students and post-doctoral fellows in many ways, including successfully completing their training and fully participating in the extramural research workforce. Pieces like these from Scientific American in 2019 and 2020, Science, and Nature Cancer as well as this recent report underscore the reality faced by some early-career researchers when balancing professional and personal responsibilities.

NIH is dedicated to fostering a well-trained and diverse biomedical research workforce, which involves supporting family-friendly policies and initiatives that balance work and family life for all biomedical researchers. Trainees and fellows supported by National Research Service Awards (NRSAs), for instance, are eligible for up to 60 calendar days (equivalent to 8 work weeks) of parental leave per year for the adoption or the birth of a child.

As part of our on-going efforts to develop programs which support family-friendly research environments for the NIH-supported workforce, NIH will begin providing an option for NRSA fellows to request support for childcare costs in new and continuation applications or as administrative supplements to existing awards effective April 8, 2021.

The NRSA childcare costs apply to full-time NIH-NRSA supported fellowship positions. Each fellow is eligible to receive $2,500 per budget period to defray childcare costs. The NRSA childcare costs are not tied to any payback obligations.

NRSA fellows are encouraged to carefully review this Guide Notice for more information, and contact relevant NIH staff with any questions if needed. Please stay tuned as related guidance is expected for NRSA supported trainees in Phase 2 of this initiative (anticipated in early fiscal year 2022).

Categories: NIH

Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)

Funding Opportunity RFA-AG-22-020 from the NIH Guide for Grants and Contracts. The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and health care practitioners, and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.
Categories: NIH

Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure

Notice NOT-MH-21-105 from the NIH Guide for Grants and Contracts
Categories: NIH

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Funding Opportunity PAR-21-137 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-702: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.
Categories: NIH

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Funding Opportunity PAR-21-136 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-703: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.
Categories: NIH

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

Funding Opportunity PAR-21-135 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-704: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this FOA encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).
Categories: NIH

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)

Funding Opportunity PAR-21-129 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-700: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-- Clinical Trial Required). This FOA is a key element of NIMHs set of FOAs to support clinical trials research across the intervention development and testing pipeline. The FOA supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This FOA is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation).
Categories: NIH

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

Funding Opportunity PAR-21-132 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-707: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline FOAs, this announcement supports confirmatory efficacy testing of non pharmacological therapeutic and preventive interventions for mental disorders in adults and children that address unmet therapeutic needs, and are consistent with the NIMH emphasis on the experimental therapeutics approach. In this approach, clinical trials should be designed to increase knowledge of the relationship between underlying disease processes and the mechanisms of action through which any intervention produces therapeutic change.
Categories: NIH

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

Funding Opportunity PAR-21-134 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-705: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this FOA encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).
Categories: NIH

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

Funding Opportunity PAR-21-130 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-701: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This FOA is a key element of NIMHs set of FOAs to support clinical trials research across the intervention development and testing pipeline. The FOA supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This FOA is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation).
Categories: NIH
Syndicate content